Biogen Inc. has disclosed uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists with improved brain penetration reported to be useful for the treatment of multiple sclerosis.

University of Antwerp has described fibroblast activation protein (FAP) inhibitors reported to be useful for the diagnosis and treatment of cancer, disorders of coagulation, glucose metabolism and inflammatory disorders.

Biotheryx Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a son of sevenless homolog 1 (SOS1) targeting moiety reported to be useful for the treatment of cancer.

Beren Therapeutics PBC has identified β-cyclodextrin derivatives reported to be useful for the treatment of cardiovascular disorders.

Haisco Pharmaceutical Group Co. Ltd. has synthesized DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Bisichem Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, asthma, stroke, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, among others.

Shenzhen Sungening Biotechnology Co. Ltd. has described kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Ribopeutic Inc. has divulged nucleic acid splicing modulators (particularly, Huntingtin [HTT; HD] [mutant] and/or transcriptional activator Myb [c-Myb]) reported to be useful for the treatment of cancer and Huntington’s disease.

Henan Medinno Pharmaceutical Technology Co. Ltd. has identified deuterated non-receptor tyrosine-protein kinase TYK2 and tyrosine-protein kinase JAK1, JAK2 and JAK3 inhibitors reported to be useful for the treatment of allergy, asthma, cancer, dermatological disorders, diabetes, eye disorders, neurodegeneration and transplant rejection, among others.